Latest releases

Nov 7, 2018 ı Corporate Releases

Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised

Oct 25, 2018 ı Corporate Releases

Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia

View all releases

Join Lundbeck

Current open positions

Browse global vacancies

Q3 2018 financial results

Watch the investor presentation

 

Download the Q3 2018 release

Latest feature

July 2018:

 

Dr. Deborah Dunsire as new President and CEO

 

Read more

Corporate film

play

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders.

 

Share price

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.